Literature DB >> 23114284

Difficult clinical management of anti-tuberculosis DRESS syndrome.

D Palmero1, J Castagnino, R M Musella, C Mosca, P González Montaner, G C de Casado.   

Abstract

We describe 11 cases of anti-tuberculosis DRESS (drug-related rash with eosinophilia and systemic symptoms) syndrome, a potentially serious complication of treatment that led to interruption of treatment for prolonged periods, systemic corticosteroid use and the resumption of treatment with less effective regimens. All patients had rash and toxic hepatitis, one died of multi-organ failure and, contrary to expectations, the evolution of tuberculosis (advanced in most cases) did not progress under corticosteroid treatment. The drug most frequently involved was rifampicin, while retreatment schemes included, in most cases, levofloxacin, ethambutol, streptomycin and cycloserine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23114284     DOI: 10.5588/ijtld.12.0441

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  10 in total

1.  DRESS syndrome presenting after initiation of mycobacterium avium complex osteomyelitis treatment.

Authors:  Paul W Blair; Douglas Herrin; Nawaf Abaalkhail; Wesley Fiser
Journal:  BMJ Case Rep       Date:  2015-10-05

2.  Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to antituberculosis drugs and associated with human herpes virus-7 (HHV-7).

Authors:  Nehal Draz; Sumona Datta; Daniel P Webster; Ian Cropley
Journal:  BMJ Case Rep       Date:  2013-07-31

3.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

4.  A Case of the Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) Following Isoniazid Treatment.

Authors:  Jin-Yong Lee; Yun-Jae Seol; Dong-Woo Shin; Dae-Young Kim; Hong-Woo Chun; Bo-Young Kim; Shin-Ok Jeong; Sang-Hyok Lim; An-Soo Jang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-01-29

Review 5.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System.

Authors:  Yung-Tsu Cho; Che-Wen Yang; Chia-Yu Chu
Journal:  Int J Mol Sci       Date:  2017-06-09       Impact factor: 5.923

6.  AdDRESSing T-cell responses to antituberculous drugs.

Authors:  R Pavlos; A Redwood; E Phillips
Journal:  Br J Dermatol       Date:  2017-02       Impact factor: 9.302

7.  Difficult clinical management of antituberculosis DRESS syndrome complicated by MRSA infection: A case report.

Authors:  Li Wang; Lin-Feng Li
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

8.  Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome Associated with Ethambutol use: A Case Report.

Authors:  Ajita Kapur; Harmeet Singh Rehan
Journal:  Curr Drug Saf       Date:  2019

9.  Strategies for Successful Treatment of Active Tuberculosis in the Setting of DRESS on RIPE.

Authors:  Quratulain Kizilbash; Adriana Vasquez; Barbara Seaworth
Journal:  Open Forum Infect Dis       Date:  2018-03-22       Impact factor: 3.835

Review 10.  Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review.

Authors:  Shiva Sharifzadeh; Amir Hooshang Mohammadpour; Ashraf Tavanaee; Sepideh Elyasi
Journal:  Eur J Clin Pharmacol       Date:  2020-10-06       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.